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conducted with 9 FM-association counsellors in 3 countries,
analysed using the same method and used to enrich the model.
Further information was captured with the analysis of 90 letters
written by patients to FM-associations. RESULTS: A total of 303
abstracts were retrieved and reviewed. Sixty-seven publications
were included and the concepts identiﬁed were grouped into the
following domains: Burden, Symptoms and Inﬂuencing Factors.
The exploratory interviews suggested that burden can be divided
into: Autonomy, Coping, Pain, Tiredness, Activities of Daily
Living, Physical Impact, Social Impact, Psychological Impact,
Cognitive Impact, Work, Sleep, Relationship to Medicine and
Disease. The letters and counsellor interviews conﬁrmed the con-
ceptual content. CONCLUSIONS: The resulting model illus-
trates how “burden” is understood by FM patients, and that all
areas of daily life are impacted by the disease. The conceptual
content will be used for the generation of items for the question-
naire. The development of a questionnaire assessing functional
impact and burden will allow the consequences of FM on
patients to be more widely recognised.
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OBJECTIVES: Background: Minor injury is a leading cause of
PED visits and a major health care burden. However, little is
known about outcomes after treatment and release; care often
lacks an evidence base. OBJECTIVES: 1) Gather initial data on
the clinical/functional outcomes after PED care, and 2) Test
both patient and proxy forms of an acute HRQOL tool in the
PED and in telephone follow-up. METHODS: Prospective con-
venience sample of pediatric patients treated for injury and dis-
charged to home. Demographic and injury data collected at the
visit; outcomes by telephone at 7–10 days. The acute Pediatric
Quality of Life Inventory 4.0 (PedsQL) was administered at
both visit and follow-up. RESULTS: Thirty-ﬁve families com-
pleted follow-up. Mean patient age = 8 years, 69% male, 49%
soft tissue injury, 31% fracture, 17% sprains, 3% CHI. Types/
locations of study injuries were in frequencies similar to those
in our ED overall. Children had a median of 3 days of pain;
24% reported 37 after the visit. Days for the child’s return to
normal activity: median 3, 37% 37. Disruption of normal
family activities in 51%, for a median of 5 days, 39% 37. Chil-
dren with school, work, or other regularly scheduled activities:
55% missed 33 days, 20% missed 37. Parents missed work or
school: mean 1 day, 22% 33. The PedsQL was found to be easy
to use, had minimal missing items, and good indication con-
struct validity (total scores inversely correlating to days of pain,
abnormal activities, and family disruption). CONCLUSIONS:
We found signiﬁcant morbidity for patients and their families
after PED visits for minor injury. In this setting, the use of the
acute PedsQL patient/proxy forms was feasible with initial indi-
cations of good construct validity. Further description and the
development/testing of a tool to quantify short-term outcomes
are prerequisites to testing effectiveness in ED minor injury
care.
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BACKGROUND: Anti-TNF therapies are efﬁcacious in clinical
trials for the treatment of RA.However, their long-term efﬁcacy in
daily practice in relation to the speciﬁc diagnosis or the use of
concomitant DMARD therapy remains to be conﬁrmed. OBJEC-
TIVES: To estimate the proportion of patients with RA, treated
with at least one anti-TNF therapy (inﬂiximab [IFX], etanercept
[ETN], or adalimumab [ADA]), who were still on the same
biologic agent after 3 yrs (36 mths) of follow-up. To estimate the
discontinuation rate of patients with RA, treated with the second
anti-TNF therapy, after discontinuing the ﬁrst one. METHODS:
Patients attending participating centers who received their ﬁrst
anti-TNF treatment between July 1, 2002 and March 31, 2004,
and who gave their consent, were invited to participate to the
study. Pts were required to be18 yrs old, with a diagnosis of RA
(as deﬁned by the ACR criteria). A total of 711 patients were
enrolled in this retrospective cohort study involving a national
representative sample of 23 rheumatology centers in Italy, selected
according to both geography and treatment setting characteristics.
A patient chart review was conducted to collect data on treatment
duration, and a diary of therapies was completed. A Kaplan–
Meier curve was calculated for each biologic anti-TNF therapy;
the event was discontinuation of the drug due to inefﬁcacy or
toxicity. RESULTS: Pts’ baseline characteristics were: female
80.8%, mean age 53.3 yrs (range 18–84 yrs), mean duration of
disease 9.4 yrs. Of 703 pts who met the inclusion criteria, 248
(35.3%) were treated with IFX, 259 (36.8%) with ETN and 196
(27.9%) with ADA. After a follow-up of 36 months, the discon-
tinuation rate was 43.2% with IFX, 25.8% with ETN and 28.0%
with ADA. The discontinuation rate of IFX compared with ETN
and ADA was statistically higher (p = 0.0001 and p = 0.0002,
respectively). The difference between ADA and ETN was not
statistically signiﬁcant (p = 0.826). Patients who discontinued the
ﬁrst agent and started the second onewere 149: ETN112, INF 12,
ADA 25. After 24 months of follow up 78% patients on ETN,
46% on ADA and 25% on INF were still on the same agent. The
RR of stopping the second agent increased by 31% (IC 95%
0.96–1.83). CONCLUSIONS: Our results show a higher discon-
tinuation rate of anti-TNF therapies in daily practice in Italy
compared with clinical trials. IFX was associated with a signiﬁ-
cantly higher rate of drug discontinuation than other anti-TNFs.
Patients who stopped the ﬁrst agent and switched to the second
one had a discontinuation risk increase of of 31%. This results
should be taken into account when ﬁrst agent fails.
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OBJECTIVES: To determine surgical treatment outcomes in
patients with cartilage defects according to operative procedures
performed. METHODS: In this 5-year retrospective cross-
sectional study patients were contacted who had been diagnosed
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